View Older Stories View More Recent Stories

Jan 28, 2020 12:59AM FDA Accepts for Priority Review Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
Jan 22, 2020 12:01PM Forty of the Nation's Brightest Young Scientists Named Finalists in Regeneron Science Talent Search 2020
Jan 10, 2020 07:00AM Regeneron to Report Fourth Quarter and Full Year 2019 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2020
Jan 9, 2020 07:01AM Regeneron (REGN) Reports Encouraging Garetosmab Phase 2 Results in Patients with Ultra-Rare Debilitating Bone Disease
Jan 9, 2020 07:00AM Regeneron Announces Encouraging Garetosmab Phase 2 Results in Patients with Ultra-Rare Debilitating Bone Disease
Jan 8, 2020 02:04PM Regeneron (REGN) Announces Publication Highlights its Costimulatory Bispecific Antibodies
Jan 8, 2020 02:02PM Publication Highlights Regeneron's Costimulatory Bispecific Antibodies, an Emerging Class of Cancer Immunotherapy
Dec 20, 2019 07:00AM Regeneron Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference
Dec 12, 2019 10:15AM Society for Science & the Public Announces Regeneron as New Title Sponsor of the International Science and Engineering Fair
Dec 12, 2019 07:00AM Regeneron and Cold Spring Harbor Laboratory Unveil New Dedicated Laboratories for Student Science Education
Dec 10, 2019 08:31AM Sanofi (SNY) and Regeneron (REGN) to restructure Antibody collaboration for Kevzara and Praluent
Dec 10, 2019 08:30AM Regeneron (REGN), Sanofi (SNY) Report Plans to Restructure Antibody Collaboration for Kevzara (sarilumab) and Praluent (alirocumab)
Dec 10, 2019 08:30AM Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
Dec 10, 2019 08:29AM Regeneron and Sanofi Announce Intent to Restructure Antibody Collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
Dec 9, 2019 06:20AM Regeneron (REGN) First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma
Dec 8, 2019 09:00AM First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma
Dec 5, 2019 07:04AM Regeneron (REGN) Reports Topline Phase 2 Data with Anti-C5 Antibody Pozelimab in Patients with a Rare Blood Disorder
Dec 5, 2019 07:00AM Regeneron Announces Positive Topline Phase 2 Data with Anti-C5 Antibody Pozelimab in Patients with a Rare Blood Disorder
Nov 27, 2019 05:00PM New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron's REGN-EB3 to ZMapp in Preventing Ebola Deaths
Nov 22, 2019 07:00AM Regeneron's Yancopoulos Receives Columbia College's Alexander Hamilton Award
Nov 12, 2019 07:30AM Regeneron Announces Upcoming Investor Conference Presentations
Nov 6, 2019 09:00AM Regeneron to Report Results from CD20xCD3 and BCMAxCD3 Bispecifics and C5 Antibody Programs at ASH Annual meeting
Nov 6, 2019 07:00AM Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer
Nov 5, 2019 06:44AM Regeneron (REGN) Reports Updates on Phase 3 Libtayo (cemiplimab) Development Program in Advanced NSCLC
Nov 5, 2019 06:40AM Regeneron Provides Updates on Phase 3 Libtayo® (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer
Nov 5, 2019 06:30AM Regeneron Reports Third Quarter 2019 Financial and Operating Results
Oct 29, 2019 08:15AM Regeneron (REGN) Announces Dupixent is Now Approved in European Union for Severe Chronic Rhinosinusitis with Nasal Polyposis
Oct 29, 2019 08:15AM Sanofi : Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis
Oct 29, 2019 08:15AM Dupixent® (dupilumab) Now Approved in European Union for Severe Chronic Rhinosinusitis with Nasal Polyposis
Oct 25, 2019 07:05AM Regeneron Ranked #2 in Science Magazine's Top Biopharma Companies to Work For
Oct 25, 2019 07:00AM Regeneron Colleagues Support 150 Community Organizations During Third Annual Day for Doing Good
Oct 18, 2019 08:30AM Regeneron Announces Upcoming Investor Conference Presentations
Oct 10, 2019 09:30AM Regeneron to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2019
Sep 20, 2019 07:01AM Regeneron (REGN), Sanofi (SNY) Report Publication of Results from Two Positive Phase 3 Trials of Dupixent (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps
Sep 20, 2019 06:59AM The Lancet Publishes Results from Two Positive Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Sep 20, 2019 06:48AM Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis  
Sep 20, 2019 06:44AM Regeneron (REGN) Announces CHMP Recommended Approval of Dupixent for Severe Chronic Rhinosinusitis with Nasal Polyposis
Sep 20, 2019 06:44AM CHMP Recommends Approval of Dupixent® (dupilumab) for Severe Chronic Rhinosinusitis with Nasal Polyposis
Sep 18, 2019 06:59AM Educational Campaign Helps Teens and Their Caregivers Tackle Everyday Challenges of Living with Moderate-to-severe Atopic Dermatitis
Sep 17, 2019 07:00AM Regeneron Debuts on Prestigious Dow Jones Sustainability World Index of Most Sustainable Companies
Aug 28, 2019 04:56PM U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9
Aug 28, 2019 04:35PM Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9
Aug 15, 2019 09:30AM Regeneron Announces Upcoming Investor Conference Presentation
Aug 14, 2019 07:02AM Regeneron (REGN) Reports Positive Topline Results from Phase 3 Trial of Evinacumab
Aug 14, 2019 07:00AM Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol
Aug 13, 2019 07:04AM Regeneron (REGN) Announces FDA Approval for EYLEA Injection Prefilled Syringe
Aug 13, 2019 07:00AM FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe
Aug 12, 2019 10:03AM Regeneron (REGN) PALM Ebola Clinical Trial Stopped Early for Superiority
Aug 12, 2019 10:01AM PALM Ebola Clinical Trial Stopped Early as Regeneron's REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths
Aug 6, 2019 06:30AM Regeneron Reports Second Quarter 2019 Financial and Operating Results
View More Recent Stories View Older Stories